Advanced glycation end products and diabetic cardiovascular disease

Cardiology in Review

Volumn 20, Issue 4, 2012, Pages 177-183

  Prasad, Anand ^a   Bekker, Peter ^b   Tsimikas, Sotirios ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

advanced glycation; atherosclerosis; diabetes mellitus

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; COLLAGEN; DNA; GLUCOSE; HEMOGLOBIN A1C; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTOSIDINE;

AGE DISTRIBUTION; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ATHEROMA; AUTOFLUORESCENCE IMAGING; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CROSS LINKING; DIABETIC CARDIOMYOPATHY; DIET; DIET RESTRICTION; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HEART SCINTISCANNING; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROTEIN DNA BINDING; REVIEW; RISK ASSESSMENT; SKIN TEST;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DIABETIC ANGIOPATHIES; DIET; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; RISK FACTORS; SKIN; SPECTROMETRY, FLUORESCENCE;

EID: 84862202592     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318244e57c     Document Type: Review

References (49)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cho-lesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
2. Preis SR, Pencina MJ, Hwang SJ, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation. 2009;120:212-220.
3. Anselmino M, Ryden L. Strategies to enhance cardiovascular disease prevention in patients with diabetes. Curr Opin Cardiol. 2009;24:461-467.
4. O'Keefe JH, Abuannadi M, Lavie CJ, et al. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011;86:128-138.
5. Meerwaldt R, Links T, Zeebregts C, et al. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol. 2008;7:29.
6. Tessier FJ. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol Biol. 2010;58:214-219.
7. Edeas M, Robert L. The Maillard reaction, its nutritional and physiopathological aspects. Introduction. Pathol Biol. 2010;58:199.
8. Rabbani N, Godfrey L, Xue M, et al. Glycation of LDL by methylglyoxal increases arterial atherogenicity: A possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes. 2011;60:1973-1980.
9. Ahmad S, Moinuddin, Dixit K, et al. Genotoxicity and immunogenicity of DNA-advanced glycation end products formed by methylglyoxal and lysine in presence of Cu2+. Biochem Biophys Res Commun. 2011;407:568-574.
10. Tamae D, Lim P, Wuenschell GE, et al. Mutagenesis and repair induced by the DNA advanced glycation end product N2-1-(carboxyethyl)-2'-deoxyguanosine in human cells. Biochemistry. 2011;50:2321-2329.
11. Wuenschell GE, Tamae D, Cercillieux A, et al. Mutagenic potential of DNA glycation: Miscoding by (R)- and (S)-N2-(1-carboxyethyl)-2'-deoxyguanosine. Biochemistry. 2010;49:1814-1821.
12. Pamplona R. Advanced lipoxidation end-products. Chem Biol Interact. 2011;192:14-20.
13. Peters AL, Davidson MB, Schriger DL, et al. A clinical approach for the diagnosis of diabetes mellitus: An analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA. 1996;276:1246-1252.
14. Hamada Y, Araki N, Koh N, et al. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem Biophys Res Commun. 1996;228:539-543.
15. Ido Y, Kilo C, Williamson JR. Interactions between the sorbitol pathway, non-enzymatic glycation, and diabetic vascular dysfunction. Nephrol Dial Transplant. 1996;11(Suppl 5):72-75.
16. Miura J, Yamagishi S, Uchigata Y, et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complicat. 2003;17:16-21.
17. Anitha B, Sampathkumar R, Balasubramanyam M, et al. Advanced glycation index and its association with severity of diabetic retinopathy in type 2 diabetic subjects. J Diabetes Complicat. 2008;22:261-266.
18. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: Relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes. 1999;48:870-880.
19. Shapiro BP, Owan TE, Mohammed SF, et al. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines. Circulation. 2008;118:1002-1010.
20. Soldatos G, Cooper ME. Advanced glycation end products and vascular structure and function. Curr Hypertens Rep. 2006;8:472-478.
21. Hartog JW, Willemsen S, van Veldhuisen DJ, et al. Effects of alagebrium, an advanced glycation end product breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail. 2011;13:899-908.
22. Willemsen S, Hartog JW, Hummel YM, et al. Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart fail-ure: Study design and baseline characteristics of the BENEFICIAL trial. Eur J Heart Fail. 2010;12:294-300.
23. Zieman SJ, Melenovsky V, Clattenburg L, et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens. 2007;25:577-583.
24. O'Rourke MF. Alagebrium: Benefit on peripheral arteries. J Card Fail. 2006;12:584.
25. Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489-497.
26. Sakata N, Meng J, Jimi S, et al. Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. Atherosclerosis. 1995;116:63-75.
27. Liu SX, Hou FF, Guo ZJ, et al. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol. 2006;26:1156-1162.
28. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes. 1985;34:938-941.
29. Nakamura Y, Horii Y, Nishino T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol. 1993;143:1649-1656.
30. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99:15596-15601.
31. Hartog JW, de Vries AP, Lutgers HL, et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci. 2005;1043:299-307.
32. Meerwaldt R, Hartog JW, Graaff R, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3687-3693.
33. Goldberg T, Cai W, Peppa M, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104:1287-1291.
34. Negrean M, Stirban A, Stratmann B, et al. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2007;85:1236-1243.
35. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;94:6474-6479.
36. Dandona P, Chaudhuri A, Mohanty P. Macronutrients, advanced glycation end products, and vascular reactivity. Diabetes Care. 2007;30:2750-2751.
37. Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110:911-16.e12.
38. Kilhovd BK, Juutilainen A, Lehto S, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: A population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol. 2005;25:815-820.
39. Kilhovd BK, Berg TJ, Birkeland KI, et al. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care. 1999;22:1543-1548.
40. Kilhovd BK, Juutilainen A, Lehto S, et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: A population-based 18 year follow-up study. Diabetologia. 2007;50:1409-1417.
41. Nin JW, Jorsal A, Ferreira I, et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12-year follow-up study. Diabetes Care. 2011;34:442-447.
42. Kiuchi K, Nejima J, Takano T, et al. Increased serum concentrations of advanced glycation end products: A marker of coronary artery disease activity in type 2 diabetic patients. Heart. 2001;85:87-91.
43. Lapolla A, Piarulli F, Sartore G, et al. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care. 2007;30:670-676.
44. Takahashi R, Imamura A, Yoshikane M, et al. High serum concentrations of pentosidine, an advanced glycation end product, are associated with low normal value of ankle-brachial index in apparently healthy men. Metab Clin Exp. 2011;60:649-654.
45. Meerwaldt R, Graaff R, Oomen PH, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324-1330.
46. Lutgers HL, Gerrits EG, Graaff R, et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia. 2009;52:789-797.
47. Lutgers HL, Graaff R, Links TP, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care. 2006;29:2654-2659.
48. Mulder DJ, van Haelst PL, Graaff R, et al. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Neth Heart J. 2009;17:162-168.
49. Noordzij M, Lefrandt J, Loeffen E, et al. Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. Intl J Cardiovasc Imag. February 19, 2011 [ePub].